Source comparison
TB-500 Results After 1 Month: Research Model Comparison
Rodent tendon injury (2.5mg 2×/week) Collagen alignment via polarized light microscopy 35% improvement vs control 68% improvement vs control Structural changes detectable but incomplete at 1 month. Peak benefit between weeks 6–8 Equine superficial digital flex
This comparison does not assign a generated winner or score.
- Rodent tendon injury (2.5mg 2×/week)
- Collagen alignment via polarized light microscopy
- 35% improvement vs control
- 68% improvement vs control
- Structural changes detectable but incomplete at 1 month. Peak benefit between weeks 6–8
- Equine superficial digital flexor tendon (SDFT) lesions
- Ultrasound echogenicity and fiber pattern
- Reduced hypoechoic zones, minimal fiber realignment
- Near-normal fiber pattern, 70–80% echogenicity restoration
- Clinical improvement (reduced lameness) precedes imaging improvement. Expect functional gains before structural normalization
- Cardiac infarct models (mouse)
- Capillary density in peri-infarct zone
- +32% capillary density vs sham
- +58% capillary density vs sham
- Angiogenic response peaks between weeks 3–5. Suggests optimal treatment window for vascular-dependent injuries
- Dermal wound healing (porcine partial-thickness burns)
- Re-epithelialization rate and scar thickness
- 40% faster closure, 22% thinner scar tissue
- Complete re-epithelialization, 45% thinner scar tissue
- TB-500 shows dose-dependent effect. Higher doses (5mg 3×/week) accelerate without improving final quality beyond 8-week standard protocol